Lung cancer
Conditions
Interventions
In lung cancer patients who had febrile neutropenia in the privious chemotherapy, garenoxacin is prescribed in the next cycle of chemotherapy from day 8 for 1 week or until grade 2 neutropenia to prev
Sponsors
Institute of Biomedical Research and Innovation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with lung cancer during chemotherapy 2)Patients who experienced febrile neutropenia 3)Dose of chemotherapy is not changed in the next cycle of the therapy. 4)Age: over 20 5)Adequate organ functions judged by laboratory tests. 6)Life expectancy: longer than 3 months 7)Wrtten informed consent
Exclusion criteria
Exclusion criteria: 1)Tumor fever 2)Complication such as severe infection or comobidities 3)History of severe allergic reaction 4)History of epilepsy or convulsant 5)Clinically significant heart disease 6)Uncontrolled diabetes 7)Routine use of NSAIDS 8)Routine use of steroids or immuno-suppressant 9)Chronic aspiration 10)Clinically significant psychological problems 11)unsuitable patients whom physitians consider
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of clinically documented febrile episode | — |
Secondary
| Measure | Time frame |
|---|---|
| The incidence of all probable infections The site of infection Pathogenic bacteria The incidence of death Safety | — |
Countries
Japan
Contacts
Public ContactAkito Hata
Institute of Biomedical Research and Innovation Division of Integrated Oncology
Outcome results
None listed